Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 vs Pembrolizumab in Advanced Mucosal and Acral Melanoma
NCT06797297Phase 2Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of IBI363 in melanoma (2 arms), sponsored by Innovent Biologics. Primary endpoint: Progression-Free Survival by IRRC at 2 years. Started Feb 2025; status: active, not recruiting.
02
Drugs
IBI363
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06797297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06797297.